| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1044948386 |
| P356 | DOI | 10.1038/SJ.BJC.6601377 |
| P953 | full work available at URL | https://doi.org/10.1038/sj.bjc.6601377 |
| https://europepmc.org/articles/PMC2394443 | ||
| https://europepmc.org/articles/PMC2394443?pdf=render | ||
| http://www.nature.com/articles/6601377.pdf | ||
| http://www.nature.com/articles/6601377 | ||
| P932 | PMC publication ID | 2394443 |
| P698 | PubMed publication ID | 14612893 |
| P5875 | ResearchGate publication ID | 9012855 |
| P50 | author | Andrew B Hassan | Q62985413 |
| P2093 | author name string | C. Markham | |
| D. D. Stocken | |||
| P2860 | cites work | New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 |
| Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial | Q29547565 | ||
| In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction. | Q32016395 | ||
| Impact of body-size measures on irinotecan clearance: alternative dosing recommendations | Q33183241 | ||
| Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer | Q33328191 | ||
| A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). | Q33329493 | ||
| Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer | Q33340167 | ||
| Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors. | Q33346436 | ||
| Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: a Southwest Oncology Group study | Q33499593 | ||
| Phase II study of gemcitabine in patients with advanced pancreatic cancer | Q34732138 | ||
| A phase II study of continuous-infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer | Q36135201 | ||
| Changes in nutritional status associated with unresectable pancreatic cancer | Q36419986 | ||
| Irinotecan, cisplatin and mitomycin in inoperable gastro-oesophageal and pancreatic cancers - a new active regimen | Q36646204 | ||
| CPT-11. The European experience | Q40916622 | ||
| A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma | Q41016197 | ||
| Chemotherapy for pancreatic carcinoma | Q41016222 | ||
| Camptothecin analog (CPT-11)-sensitive human pancreatic tumor cell line QGP-1N shows resistance to SN-38, an active metabolite of CPT-11. | Q41598788 | ||
| Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial | Q43693195 | ||
| Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer | Q43850218 | ||
| Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer | Q43899629 | ||
| Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer | Q44529248 | ||
| Comments on: Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies, Andreyev et al., Eur J Cancer 1998, 34, pp. 503-509. | Q47270161 | ||
| Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? | Q47282777 | ||
| A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study Group. | Q53553125 | ||
| Treatment and survival in 13560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: An epidemiological study | Q62065473 | ||
| CPT-11-induced cholinergic effects in cancer patients | Q70524853 | ||
| A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer | Q71528572 | ||
| Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice | Q71579245 | ||
| Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study | Q72327076 | ||
| Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin | Q73330191 | ||
| A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma | Q74635392 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pancreatic cancer | Q212961 |
| oncology | Q162555 | ||
| P304 | page(s) | 1860-1864 | |
| P577 | publication date | 2003-11-01 | |
| 2003-11-17 | |||
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | A phase II irinotecan-cisplatin combination in advanced pancreatic cancer | |
| A phase II irinotecan–cisplatin combination in advanced pancreatic cancer | |||
| P478 | volume | 89 |
Search more.